^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    zanzalintinib (XL092)

    i
    Other names: XL092, XL-092, XL 092
    Associations

    News

    Trials
    Company:
    Exelixis
    Drug class:
    Tyrosine kinase inhibitor
    Related drugs:
    Associations

    News

    Trials
    7d
    A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) (clinicaltrials.gov)
    P2, N=70, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open
    |
    zanzalintinib (XL092)
    10d
    A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Exelixis
    New P2 trial
    |
    zanzalintinib (XL092)
    17d
    A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) (2024-517136-21-00)
    P2/3, N=398, Recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    Cabometyx (cabozantinib tablet) • Welireg (belzutifan) • zanzalintinib (XL092)
    17d
    XL092-311: A Phase 2/3 clinical trial with zanzalintinib versus everolimus (2025-521043-20-00)
    P2/3, N=172, Not yet recruiting, Exelixis Inc.
    New P2/3 trial
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    everolimus • zanzalintinib (XL092)
    19d
    Myeloid-derived suppressor cells and regulatory T cells in colorectal cancer: a synergistic immunosuppressive axis and emerging therapeutic opportunities. (PubMed, Front Immunol)
    Emerging clinical and translational data indicate that disrupting this axis can sensitize MSS-CRC to ICIs: for example, Zanzalintinib combined with Atezolizumab reported survival benefit in the STELLAR-303 trial, and dual blockade of novel checkpoints with PD-(L)1 has been associated with enhanced immune activation in solid tumors. Targeting the MDSC-Treg axis therefore represents a promising strategy to overcome immunotherapy resistance in MSS/pMMR CRC.
    Review • Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • CD73 (5'-Nucleotidase Ecto) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • TLR4 (Toll Like Receptor 4) • CXCL3 (C-X-C Motif Chemokine Ligand 3)
    |
    Tecentriq (atezolizumab) • zanzalintinib (XL092)
    22d
    STELLAR-002: Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=1314, Recruiting, Exelixis | Active, not recruiting --> Recruiting
    Enrollment open
    |
    FH (Fumarate Hydratase)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016) • zanzalintinib (XL092)
    2ms
    Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • zanzalintinib (XL092)
    3ms
    Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs) (clinicaltrials.gov)
    P2, N=32, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    zanzalintinib (XL092)
    3ms
    Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    Keytruda (pembrolizumab) • zanzalintinib (XL092)
    3ms
    A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Active, not recruiting | Initiation date: May 2026 --> Dec 2025
    Enrollment closed • Trial initiation date
    |
    zanzalintinib (XL092)
    3ms
    LITESPARK-033: A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) (clinicaltrials.gov)
    P3, N=904, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Cabometyx (cabozantinib tablet) • Welireg (belzutifan) • zanzalintinib (XL092)
    3ms
    Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov)
    P1/2, N=314, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)